Mentions
Extended reach
Total likes
Video views
AI synopsis
Several discussions highlight the impactful results of the TRISCEND II trial, such as the phrase 'substantial improvement in patients’ symptoms' and noting that 'TTVR offers clinical and quality-of-life benefits.' The choice of language—terms like 'major symptomatic improvement' and 'reassuring benefit'—conveys a positive tone, fostering excitement about the study’s implications for future medical practice.
Most discussions reflect strong agreement regarding the positive findings of the TRISCEND II trial, highlighting substantial patient benefits.
There is notable curiosity and enthusiasm toward the study's results and implications.
The depth of engagement is moderate, with some posts requesting further insights and analysis on methods but lacking extensive dialogue.
Many participants perceive the findings as significant, emphasizing the potential for improved patient care and outcomes.
#TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the #TRISCENDII trial led by Drs. @arnoldgehrke, @hahn_rt, @SusheelKodaliMD, @djc795, and team now available in #JACC https://t.co/PRYgeXIxrI #vhdTR https://t.co/Qet6iByeWU
#TCT2024: Drs. @arnoldgehrke, @hahn_rt, @SusheelKodaliMD, @djc795, et al present secondary analyses from the #TRISCENDII pivotal trial with #simpub in #JACC They find that #TTVR for #vhdTR is assoc w/ sustained health status improvement at 1 yr https://t.co/PRYgeXIxrI https://t.co/4m951Xo0f5
TRISCEND II Pivotal Trial results show transcatheter tricuspid valve replacement offers clinical and quality-of-life benefits compared with medical therapy.
Very interesting work in @JACCJournals. Major symptomatic improvement Suspect tricuspid valve interventions really start taking off. A lot of technical skill required for some of these procedures though Thoughts? https://t.co/YNhJ238fNw https://t.co/yMUyqoW1Xm
#TCT2024 ICYMI: #JACC AE Dr. @denniskomd talks with Dr. @arnoldgehrke about the health status analysis from the #TRISCENDII pivotal trial
(7/13) Second, Drs. @arnoldgehrke, @djc795, et al publish outcomes from the TRISCEND II pivotal trial of transcatheter tricuspid valve replacement https://t.co/VgggV0XiOR #JACC #TTVR #vhdTR https://t.co/pvGhaxuOi3
In this JACC Journal Club session, we analyze cutting-edge research on tricuspid transcatheter interventions, emphasizing the TRISCEND II trial. Our experts discuss patient selection, procedural techniques, and…
In this JACC Masterclass, Aakriti Gupta MD FACC and Martin B Leon MD FACC discuss the impact of severe tricuspid regurgitation on health status and the TRISCEND II trial findings. They highlight significant improvements…
In this video, Dr. Suzanne Arnold discusses the TRISCEND II trial, which examined the impacts of transcatheter tricuspid valve replacement on quality of life for patients with severe tricuspid regurgitation. Results…
1-year results from TRISCEND II trial show improved quality of life after transcatheter tricuspid valve replacement. #HeartHealth #MedicalResearch https://t.co/DbG3db7uZ6 https://t.co/lFyZv29LyC
نتائج السنة الأولى من تجربة TRISCEND II تظهر تحسن في جودة الحياة بعد استبدال الصمام الثلاثي عبر القسطرة. #صحة_القلب #البحث_الطبي [LINK:استبدال الصمام الثلاثي عبر القسطرة] https://t.co/Rg7qyWqatwاستبدال_الصمام_الأورطي_عبر_القسطرة https://t.co/TQkoW5DJTz https://t.co/BQQ8Wp2YEn
RT @RichardAFerraro: Very interesting work in @JACCJournals. Major symptomatic improvement Suspect tricuspid valve interventions really st…
TRILUMINATE(および心臓リモデリングを評価したサブ解析)やTRISCEND IIも紹介されてます https://t.co/zl56nZ3eo9 https://t.co/u93QSO57e9 https://t.co/sZ2YhGmdXQ
RT @RichardAFerraro: Very interesting work in @JACCJournals. Major symptomatic improvement Suspect tricuspid valve interventions really st…
RT @RichardAFerraro: Very interesting work in @JACCJournals. Major symptomatic improvement Suspect tricuspid valve interventions really st…
RT @JACCJournals: (7/13) Second, Drs. @arnoldgehrke, @djc795, et al publish outcomes from the TRISCEND II pivotal trial of transcatheter tr…
(7/13) Second, Drs. @arnoldgehrke, @djc795, et al publish outcomes from the TRISCEND II pivotal trial of transcatheter tricuspid valve replacement https://t.co/VgggV0XiOR #JACC #TTVR #vhdTR https://t.co/pvGhaxuOi3
RT @RichardAFerraro: Very interesting work in @JACCJournals. Major symptomatic improvement Suspect tricuspid valve interventions really st…
Very interesting work in @JACCJournals. Major symptomatic improvement Suspect tricuspid valve interventions really start taking off. A lot of technical skill required for some of these procedures though Thoughts? https://t.co/YNhJ238fNw https://t.co/yMUyqoW1Xm
Findings from TRISCEND II show the KCCQ is a powerful tool for assessing symptoms & QoL in patients with severe TR undergoing TTVR, highlighting its versatility beyond HF. https://t.co/UTo8C8kS1I #PatientReportedOutcomes #JACC https://t.co/4UXAFKvXVI
https://t.co/o7ElzPIfQW TRISCEND II authors offer several lines of circumstantial evidence suggesting a true biologic effect of TTVR on health status benefit. Which one of these is most convincing?
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
#TCT2024 ICYMI: #JACC AE Dr. @denniskomd talks with Dr. @arnoldgehrke about the health status analysis from the #TRISCENDII pivotal trial
RT @crfheart: TRISCEND II Pivotal Trial results show transcatheter tricuspid valve replacement offers clinical and quality-of-life benefits…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @drbennisahmed: Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial treatmen…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @crfheart: TRISCEND II Pivotal Trial results show transcatheter tricuspid valve replacement offers clinical and quality-of-life benefits…
RT @crfheart: TRISCEND II Pivotal Trial results show transcatheter tricuspid valve replacement offers clinical and quality-of-life benefits…
Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial treatment of severe or greater TR with TTVR+OMT resulted in substantial improvement in patients’ symptoms, function, and quality of life https://t.co/DZiK9KdBpD https://t.co/YyzjtyZ5of
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @JACCJournals: #TCT2024: Drs. @arnoldgehrke, @hahn_rt, @SusheelKodaliMD, @djc795, et al present secondary analyses from the #TRISCENDII…
RT @JACCJournals: #TCT2024: Drs. @arnoldgehrke, @hahn_rt, @SusheelKodaliMD, @djc795, et al present secondary analyses from the #TRISCENDII…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @JACCJournals: #TCT2024: Drs. @arnoldgehrke, @hahn_rt, @SusheelKodaliMD, @djc795, et al present secondary analyses from the #TRISCENDII…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
RT @JACCJournals: #TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the…
#TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the #TRISCENDII trial led by Drs. @arnoldgehrke, @hahn_rt, @SusheelKodaliMD, @djc795, and team now available in #JACC https://t.co/PRYgeXIxrI #vhdTR https://t.co/Qet6iByeWU
1/ https://t.co/o7ElzPIfQW Quality of benefit in TRISCEND II Authors offer several lines of evidence suggesting a true biologic effect of TTVR 1. Magnitude & durability of benefit are reassuring. How so?
RT @JACCJournals: #TCT2024: Drs. @arnoldgehrke, @hahn_rt, @SusheelKodaliMD, @djc795, et al present secondary analyses from the #TRISCENDII…
RT @crfheart: TRISCEND II Pivotal Trial results show transcatheter tricuspid valve replacement offers clinical and quality-of-life benefits…
RT @crfheart: TRISCEND II Pivotal Trial results show transcatheter tricuspid valve replacement offers clinical and quality-of-life benefits…
RT @crfheart: TRISCEND II Pivotal Trial results show transcatheter tricuspid valve replacement offers clinical and quality-of-life benefits…
Compared with OMT alone, treatment of patients with symptomatic and severe or greater TR with TTVR+OMT resulted in substantial improvement in patients’ symptoms, function, and quality of life. These benefits were evident 30 days https://t.co/6qG5snUPl2
RT @crfheart: TRISCEND II Pivotal Trial results show transcatheter tricuspid valve replacement offers clinical and quality-of-life benefits…
RT @crfheart: TRISCEND II Pivotal Trial results show transcatheter tricuspid valve replacement offers clinical and quality-of-life benefits…
RT @crfheart: TRISCEND II Pivotal Trial results show transcatheter tricuspid valve replacement offers clinical and quality-of-life benefits…
RT @crfheart: TRISCEND II Pivotal Trial results show transcatheter tricuspid valve replacement offers clinical and quality-of-life benefits…
TRISCEND II Pivotal Trial results show transcatheter tricuspid valve replacement offers clinical and quality-of-life benefits compared with medical therapy.
RT @JACCJournals: #TCT2024: Drs. @arnoldgehrke, @hahn_rt, @SusheelKodaliMD, @djc795, et al present secondary analyses from the #TRISCENDII…
RT @JACCJournals: #TCT2024: Drs. @arnoldgehrke, @hahn_rt, @SusheelKodaliMD, @djc795, et al present secondary analyses from the #TRISCENDII…
RT @JACCJournals: #TCT2024: Drs. @arnoldgehrke, @hahn_rt, @SusheelKodaliMD, @djc795, et al present secondary analyses from the #TRISCENDII…
Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial | Journal of the American College of Cardiology https://t.co/hhZ1SdlFjK
RT @JACCJournals: #TCT2024: Drs. @arnoldgehrke, @hahn_rt, @SusheelKodaliMD, @djc795, et al present secondary analyses from the #TRISCENDII…
#TCT2024: Drs. @arnoldgehrke, @hahn_rt, @SusheelKodaliMD, @djc795, et al present secondary analyses from the #TRISCENDII pivotal trial with #simpub in #JACC They find that #TTVR for #vhdTR is assoc w/ sustained health status improvement at 1 yr https://t.co/PRYgeXIxrI https://t.co/4m951Xo0f5